BIB vs. BIS
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares UltraShort Nasdaq Biotechnology (BIS).
BIB and BIS are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. BIS is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (-200%). It was launched on Apr 7, 2010. Both BIB and BIS are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
BIB vs. BIS - Performance Comparison
Loading graphics...
BIB vs. BIS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 2.18% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
BIS ProShares UltraShort Nasdaq Biotechnology | -6.20% | -45.95% | 4.79% | -6.54% | -2.14% | -14.74% | -56.01% | -41.01% | 5.14% | -36.98% |
Returns By Period
In the year-to-date period, BIB achieves a 2.18% return, which is significantly higher than BIS's -6.20% return. Over the past 10 years, BIB has outperformed BIS with an annualized return of 6.84%, while BIS has yielded a comparatively lower -24.45% annualized return.
BIB
- 1D
- 9.12%
- 1M
- -7.53%
- YTD
- 2.18%
- 6M
- 37.07%
- 1Y
- 70.62%
- 3Y*
- 15.61%
- 5Y*
- -0.24%
- 10Y*
- 6.84%
BIS
- 1D
- -8.92%
- 1M
- 5.69%
- YTD
- -6.20%
- 6M
- -31.27%
- 1Y
- -50.91%
- 3Y*
- -21.67%
- 5Y*
- -15.13%
- 10Y*
- -24.45%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. BIS - Expense Ratio Comparison
Both BIB and BIS have an expense ratio of 0.95%.
Return for Risk
BIB vs. BIS — Risk / Return Rank
BIB
BIS
BIB vs. BIS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares UltraShort Nasdaq Biotechnology (BIS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIB | BIS | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.50 | -1.09 | +2.59 |
Sortino ratioReturn per unit of downside risk | 2.04 | -1.73 | +3.77 |
Omega ratioGain probability vs. loss probability | 1.26 | 0.81 | +0.45 |
Calmar ratioReturn relative to maximum drawdown | 2.76 | -0.76 | +3.52 |
Martin ratioReturn relative to average drawdown | 9.82 | -1.06 | +10.88 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BIB | BIS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.50 | -1.09 | +2.59 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.01 | -0.35 | +0.34 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.15 | -0.53 | +0.67 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.34 | -0.68 | +1.02 |
Correlation
The correlation between BIB and BIS is -0.96. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Dividends
BIB vs. BIS - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.60%, less than BIS's 4.91% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.60% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% |
BIS ProShares UltraShort Nasdaq Biotechnology | 4.91% | 5.25% | 3.73% | 1.75% | 0.00% | 0.00% | 0.45% | 2.11% | 0.37% |
Drawdowns
BIB vs. BIS - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum BIS drawdown of -99.86%. Use the drawdown chart below to compare losses from any high point for BIB and BIS.
Loading graphics...
Drawdown Indicators
| BIB | BIS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -99.86% | +32.62% |
Max Drawdown (1Y)Largest decline over 1 year | -21.73% | -64.06% | +42.33% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -73.87% | +8.01% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -95.07% | +28.87% |
Current DrawdownCurrent decline from peak | -24.88% | -99.85% | +74.97% |
Average DrawdownAverage peak-to-trough decline | -32.85% | -89.92% | +57.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.52% | 46.28% | -39.76% |
Volatility
BIB vs. BIS - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) and ProShares UltraShort Nasdaq Biotechnology (BIS) have volatilities of 17.28% and 17.39%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BIB | BIS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.28% | 17.39% | -0.11% |
Volatility (6M)Calculated over the trailing 6-month period | 28.86% | 29.15% | -0.29% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.37% | 47.18% | +0.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.32% | 43.50% | -0.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.78% | 46.64% | +0.14% |